Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 25;6(8):FSO600.
doi: 10.2144/fsoa-2020-0024.

Estimation of US patients with cancer who may respond to cytotoxic chemotherapy

Edward B Maldonado  1 , Scott Parsons  1 , Emerson Y Chen  1 , Alyson Haslam  1 , Vinay Prasad  2
Affiliations

Estimation of US patients with cancer who may respond to cytotoxic chemotherapy

Edward B Maldonado et al. Future Sci OA. .

Abstract

Aims patients & methods: In this retrospective review, we sought to estimate the proportion of patients in the USA with advanced or metastatic cancer who are eligible for and may respond to recommended first-line cytotoxic chemotherapy based on National Comprehensive Cancer Network treatment guidelines.

Results: Among 609,640 patients, we estimate 479,823 (78.7%, 95% CI: 78.6-78.8%) may be eligible for cytotoxic chemotherapy while 189,159 out of 609,640 patients (31.0%, 95% CI: 30.9-31.1%) may have achieved treatment response. The average objective response rate from these regimens was 48.6% (range 9.2 to 90.6%).

Conclusion: Given the large role of cytotoxic agents in cancer, drug development in this space may remain of interest in specific cancer types, and regulatory approval of novel oncology drugs may justify head-to-head comparisons against cytotoxic regimens.

Keywords: chemotherapy; cytotoxic; oncology drugs.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure V Prasad reports research funding from Arnold Ventures; royalties from Johns Hopkins Press and Medscape; honoraria from Grand Rounds/lectures for universities, medical centers, nonprofits and professional societies; consulting for UnitedHealthcare; speaking fees from Evicore; and Plenary Session podcast has Patreon backers. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.
Figure 1.. Estimation of US patients who are eligible for and may respond to cytotoxic chemotherapy, 2018.
Figure 2.
Figure 2.. Estimated average response rates for cytotoxic chemotherapy regimens, 2018.
See this image and copyright information in PMC

References

    1. Marquart J, Chen EY, Prasad V. Estimation of the percentage of US patients with cancer who respond to genome-driven oncology. JAMA Oncol. 4(8), 1093–1098 (2018). - PMC - PubMed

    2. •• Offers a similar methodological analysis of genome-targeted therapies, eligibility and potential benefit amongst US patients with advanced or metastatic cancers.

    1. Haslam A, Gill J, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs. JAMA Netw. Open 3(3), e200423 (2020). - PMC - PubMed

    2. •• Offers a similar methodological analysis of immunotherapies, eligibility and potential benefit amongst US patients with cancer.

    1. Haslam A, Prasad V. et al. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drug. JAMA Netw. Open. 2(5), e192535 (2019). - PMC - PubMed
    1. National Comprehensive Cancer Network Guidelines for Treatment of Cancer by Site. National Comprehensive Cancer Network (2018). www.nccn.org/professionals/physician_gls/default.aspx#site
    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. CA Cancer J. Clin. 68(1), 7–30 (2018). - PubMed